The estimated Net Worth of Andrew Scott Walton is at least $1.82 million dollars as of 9 April 2012. Mr. Walton owns over 4,000 units of Oxford Immunotec Global PLC stock worth over $490,311 and over the last 18 years he sold OXFD stock worth over $1,234,635. In addition, he makes $95,943 as Independent Director at Oxford Immunotec Global PLC.
Sign up
Mr. Walton OXFD stock SEC Form 4 insiders trading
Andrew has made over 9 trades of the Oxford Immunotec Global PLC stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 4,000 units of OXFD stock worth $367,280 on 9 April 2012.
The largest trade he's ever made was exercising 5,000 units of Oxford Immunotec Global PLC stock on 6 October 2010 worth over $292,850. On average, Andrew trades about 529 units every 39 days since 2007. As of 9 April 2012 he still owns at least 22,297 units of Oxford Immunotec Global PLC stock.
You can see the complete history of Mr. Walton stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrew Walton biography
Andrew Scott Walton is Independent Director of the Company. He served as chief executive officer of Inform Diagnostics (formerly known as Miraca Life Sciences), the largest independent anatomic pathology provider in the United States, from November 2017 until July of 2018. From 2012 to 2017, Mr. Walton served as president and chief executive officer of Ameritox, a company that offers laboratory testing and practice management tools to help clinicians coordinate and optimize the care of chronic pain and behavioral health patients. Prior to joining Ameritox, from 2005 to 2012, he held senior leadership positions within Laboratory Corporation of America, most recently serving as executive vice president of the esoteric testing businesses, and as a member of LabCorp’s five person executive committee. Prior to this, Mr. Walton led LabCorp’s strategic planning and merger & acquisition activities, and also served as the company’s chief information officer. Earlier in his career, he held management consultant positions with PricewaterhouseCoopers, KPMG and Ernst & Young where he focused on the healthcare market. Mr. Walton earned his bachelor’s degree from Yale University and his Master of Business Administration from Harvard Business School.
What is the salary of Andrew Walton?
As the Independent Director of Oxford Immunotec Global PLC, the total compensation of Andrew Walton at Oxford Immunotec Global PLC is $95,943. There are 7 executives at Oxford Immunotec Global PLC getting paid more, with Peter Wrighton-Smith having the highest compensation of $2,151,490.
How old is Andrew Walton?
Andrew Walton is 53, he's been the Independent Director of Oxford Immunotec Global PLC since 2017. There are 7 older and 3 younger executives at Oxford Immunotec Global PLC. The oldest executive at Oxford Immunotec Global PLC is Richard Sandberg, 77, who is the Independent Director.
What's Andrew Walton's mailing address?
Andrew's mailing address filed with the SEC is C/O OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, ABINGDON, OXFORDSHIRE, X0, OX14 4RZ.
Insiders trading at Oxford Immunotec Global PLC
Over the last 11 years, insiders at Oxford Immunotec Global PLC have traded over $13,598,906 worth of Oxford Immunotec Global PLC stock and bought 47,600 units worth $549,576 . The most active insiders traders include James R Tobin, Peter Wrighton Smith et Ronald Asbury Andrews. On average, Oxford Immunotec Global PLC executives and independent directors trade stock every 36 days with the average trade being worth of $536,006. The most recent stock trade was executed by Patrick J Balthrop on 20 May 2020, trading 4,000 units of OXFD stock currently worth $49,920.
What does Oxford Immunotec Global PLC's logo look like?
Complete history of Mr. Walton stock trades at Oxford Immunotec Global PLC et Labcorp
Oxford Immunotec Global PLC executives and stock owners
Oxford Immunotec Global PLC executives and other stock owners filed with the SEC include:
-
Peter Wrighton-Smith,
Chief Executive Officer, Director -
Matthew McLaughlin,
Chief Financial Officer -
Richard Sandberg,
Independent Director -
Patrick Balthrop,
Independent Chairman of the Board -
Herman Rosenman,
Independent Director -
James Tobin,
Independent Director -
Patricia Randall,
Independent Director -
Andrew Walton,
Independent Director -
Mark Klausner,
Independent Director -
Ronald Andrews,
Independent Director -
Janet Kidd,
General Counsel, Company Secretary -
Herm Rosenman,
-
Richard M. Altieri,
Chief Financial Officer -
Peter Edwardson,
Chief Operations Officer -
Stephen L Spotts,
Director -
Jeff R. Schroeder,
Chief Commercial Officer -
Richard Wenstrup,
Chief Medical Officer -
Stefan C Linn,
Chief Operating Officer -
Elizabeth M Keiley,
VP & General Counsel -
Lifesciences I, L.P.Clarus ...,
-
Leaf Ventures Ii, L.P.New L...,